This post has been read 13722 times!
WASHINGTON, Dec 14: Pfizer said on Tuesday tests confirm its new COVID antiviral pills, Paxlovid, cut the risk of hospitalization or death by 89 per cent for people at high-risk of severe COVID-19 of all variants, including Omicron, within the first three days of their symptoms.
Another trial, including unvaccinated adults, reveal a 70 per cent reduction in the risk of hospitalization and no deaths. “Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus,” Pfizer CEO Albert Bourla said in a statement. “We are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic.” (KUNA)